DTIC-NPs-DR5 mAb may possess not only the anti-cancer effects of DTIC and DR5 mAb, but also additional favorable pharmacokinetic properties, such as a long systemic circulation time and actively targeted distribution. This evidence concerns the gene TNFRSF10B and cancer.